Published in Biometrics on February 04, 2013
Prediction of coronary artery disease risk based on multiple longitudinal biomarkers. Stat Med (2015) 0.82
A longitudinal model for disease progression was developed and applied to multiple sclerosis. J Clin Epidemiol (2015) 0.82
Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation. Stat Methods Med Res (2014) 0.82
Joint Analyses of Longitudinal and Time-to-Event Data in Research on Aging: Implications for Predicting Health and Survival. Front Public Health (2014) 0.80
A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening. J R Stat Soc Ser A Stat Soc (2015) 0.79
Comparison of methods for estimating the effect of salvage therapy in prostate cancer when treatment is given by indication. Stat Med (2013) 0.78
A prediction model for colon cancer surveillance data. Stat Med (2015) 0.76
Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer. Stat Med (2016) 0.75
Personalized screening intervals for biomarkers using joint models for longitudinal and survival data. Biostatistics (2015) 0.75
Dynamic predictions using flexible joint models of longitudinal and time-to-event data. Stat Med (2017) 0.75
On longitudinal prediction with time-to-event outcome: Comparison of modeling options. Biometrics (2016) 0.75
Bayesian joint ordinal and survival modeling for breast cancer risk assessment. Stat Med (2016) 0.75
An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiat Oncol (2017) 0.75
Dynamics of Disease Progression and Gastrostomy Tube Placement in Children and Adolescents with Cystic Fibrosis: Application of Joint Models for Longitudinal and Time-to-Event Data. Intern Med Rev (Wash D C) (2016) 0.75
Predicting virological decay in patients starting combination antiretroviral therapy. AIDS (2016) 0.75
Joint partially linear model for longitudinal data with informative drop-outs. Biometrics (2016) 0.75
Dynamic predictions in Bayesian functional joint models for longitudinal and time-to-event data: An application to Alzheimer's disease. Stat Methods Med Res (2017) 0.75
Joint modelling of longitudinal 3MS scores and the risk of mortality among cognitively impaired individuals. PLoS One (2017) 0.75
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Joint modelling of longitudinal measurements and event time data. Biostatistics (2000) 6.23
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics (2009) 2.38
Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data. Biometrics (2011) 1.90
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys (2008) 1.63
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol (2005) 1.45
Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res (2012) 1.34
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys (2003) 1.15
The effect of salvage therapy on survival in a longitudinal study with treatment by indication. Stat Med (2010) 1.06
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A (2009) 5.39
BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-phase amplified DNA colonies. Nucleic Acids Res (2006) 4.93
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2002) 3.93
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol (2009) 3.86
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2004) 2.18
Rapid functional dissection of genetic networks via tissue-specific transduction and RNAi in mouse embryos. Nat Med (2010) 2.01
Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2003) 1.89
Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst (2003) 1.89
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol (2010) 1.87
Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem (2005) 1.75
Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation. Int J Radiat Oncol Biol Phys (2007) 1.75
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys (2003) 1.65
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys (2008) 1.63
Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.61
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys (2005) 1.59
PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J (2008) 1.58
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer (2007) 1.54
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys (2012) 1.52
Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause (2003) 1.50
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49
Screening for prostate cancer. CA Cancer J Clin (2009) 1.48
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood (2006) 1.46
The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. Biostatistics (2002) 1.46
Chilling outweighs photoperiod in preventing precocious spring development. Glob Chang Biol (2013) 1.43
Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys (2010) 1.42
Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes (2014) 1.42
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2013) 1.40
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.39
Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.35
Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem (2003) 1.34
Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum (2009) 1.30
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.27
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer (2005) 1.24
Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol (2002) 1.23
Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys (2008) 1.23
Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol (2007) 1.22
Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol (2004) 1.21
Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys (2005) 1.21
Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol (2012) 1.21
The impact of explicit values clarification exercises in a patient decision aid emerges after the decision is actually made: evidence from a randomized controlled trial. Med Decis Making (2012) 1.21
Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. Biochem J (2004) 1.20
Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys (2008) 1.19
Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol (2002) 1.19
Changes in the respiratory pattern during radiotherapy for cancer in the lung. Radiother Oncol (2006) 1.19
KCTD5, a putative substrate adaptor for cullin3 ubiquitin ligases. FEBS J (2008) 1.18
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys (2005) 1.17
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol (2011) 1.16
Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol (2002) 1.16
Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst (2007) 1.15
Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys (2010) 1.15
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.14
Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys (2009) 1.14
Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J Biol Chem (2001) 1.14
Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys (2010) 1.13
Prostate-specific antigen in the early detection of prostate cancer. CMAJ (2007) 1.13
Computed tomography guided management of interfractional patient variation. Semin Radiat Oncol (2005) 1.12
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.11
Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem (2006) 1.11
Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem (2004) 1.11
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials (2013) 1.10
Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc (2008) 1.10
Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys (2010) 1.09
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol (2003) 1.08
SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. Mol Immunol (2007) 1.07
The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2012) 1.07
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys (2007) 1.06
The effect of salvage therapy on survival in a longitudinal study with treatment by indication. Stat Med (2010) 1.06
Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol (2011) 1.06
Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA Study. Obesity (Silver Spring) (2008) 1.06
An integrated systems biology approach to the study of preterm birth using "-omic" technology--a guideline for research. BMC Pregnancy Childbirth (2011) 1.06
Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer (2003) 1.06
Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol (2005) 1.06
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.05
Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J Biol Chem (2002) 1.05